Currently funded projects

Filter
BsAb directed to PSMA and CD3 recruit T cells against tumor cells (A). To avoid “off target” activation and thus side effects (B), expression of the selected target antigen should be restricted to tumor cells.

Drug substance production of the bispecific PSMAxCD3 antibody CC-1 to enable the conduct of a clinical study in patients with squamous cell carcinoma of the lung

Institution: Klinische Kooperationseinheit Translationale Immunologie, Deutsches Konsortium für Translationale Krebsforschung (DKTK), Deutsches Krebsforschungszentrum (DKFZ), Department für Innere Medizin, Universitätsklinikum Tübingen

The project involves the preparation and execution of a first-in-man study to investigate the potential of novel small molecule ferroptosis inhibitors for the prevention of ischemia/reperfusion injury upon liver transplantation.

Evaluation of ferroptosis inhibition for the treatment of ischemia/reperfusion injury upon liver transplantation: A first-in-man pilot study

Institution: Institut für Metabolismus und Zelltod, Helmholtz Zentrum München
Applicant: Dr. Marcus Conrad, Helmholtz Zentrum München

DKFZ-682 is a new inhibitor of the redox-buffer system regulated by thioredoxin. This system is particularly unstable in SCLC and thus enables the selectivity of the drug. The project promotes therapy optimization in a tumor model.

Preclinical optimization of a therapy concept based on novel gold-DTC complexes for lasting control of small cell lung cancer

Institution: Deutsches Krebsforschungzentrum (DKFZ)
Applicant: Nikolas Gunkel

LRIG2 will be inhibited by monoclonal antibodies what decreases lipid retention in adipocytes and reduces fat tissues. Investigations will be done in mice, pigs, and humans.

Obesity therapy and prevention by LRIG2 inhibition – a translational validation in a pig model

Institution: Institut für Molekulare Tierzucht und Biotechnologie, Ludwig-Maximilians-Universität München, Genzentrum
Applicant: PD Dr. Maik Dahlhoff, LMU München, Genzentrum

Sonja Johannsmeier and Dr. Dag Heinemann examine a fluorescent sample.

Development of an endoscopic system for chromatically contrasted imaging and laser-based removal of bone cement in revision arthroplasty

Institution: Laser Zentrum Hannover e.V., Abteilung Industrielle und Biomedizinische Optik
Applicant: Dr. Tammo Ripken, Abteilungsleiter Industrielle und Biomedizinische Optik, Laser Zentrum Hannover e.V.

CCL25 based regeneration for treatment of osteoarthritis. Concept of product design and application.

CCL25-based tissue regeneration for the treatment of osteoarthritis

Institution: Charité – Universitätsmedizin Berlin
Applicant: Dr. rer. nat. Michael Sittinger

Project plan to obtain, propagate, and transplant  primary human muscle stem in an autologous setting.

Patient-derived muscle stem cells for the treatment of muscle wasting and muscular defects

Institution: Charité Campus Buch, Experimental and Clinical Research Center
Applicant: Prof. Dr. Simone Spuler, Charité Universitätsmedizin Berlin und Max-Delbrück Zentrum für Molekulare Medizin

Monoclonal antibodies, like 6A10 targeting the protein CA12, can be generated by extracellular vesicles. These antibodies are specific for tumor-associated factors and can therefore bind to tumor cells.

Preclinical Evaluation of a proprietary antibody for cancer treatment

Institution: Helmholtz Zentrum München, Deutsches Zentrum für Gesundheit und Umwelt (HMGU) und Klinikum der Universität München (KUM)
Applicant: Prof. Dr. Reinhard Zeidler

The bone marrow microenvironment is a complex entity composed of different cell populations and other elements. Within this complex system, periostin plays a key role for the intercellular communication.

Targeting the extracellular matrix in the bone marrow to augment normal and impair malignant haematopoiesis

Institution: Georg-Speyer-Haus,Institut für Tumorbiologie und Experimentelle Therapie
Applicant: Prof. Dr. med. Daniela Krause, Georg-Speyer-Haus

The dual farnesoid X receptor and soluble epoxide hydrolase modulator (FXRA/sEHi) was designed by rational pharmacophore fusion and is currently evaluated for (synergistic) efficacy and improved safety in preclinical studies.

Preclinical characterization of an innovative dual FXR/sEH modulator as experimental drug to treat non-alcoholic steatohepatitis

Institution: Institut für Pharmazeutische Chemie, Johann Wolfgang Goethe-Universität Frankfurt
Applicant: Dr. phil. nat. Daniel Merk, Johann Wolfgang Goethe-Universität Frankfurt